
RealRate

PHARMACEUTICAL 2021

Biohaven Pharmaceutical Holding Co Ltd.



Rank 346 of 402





RealRate

PHARMACEUTICAL 2021

Biohaven Pharmaceutical Holding Co Ltd.



Rank 346 of 402

The relative strengths and weaknesses of Biohaven Pharmaceutical Holding Co Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biohaven Pharmaceutical Holding Co Ltd. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 9.9% points. The greatest weakness of Biohaven Pharmaceutical Holding Co Ltd. is the variable Other Liabilities, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is -157%, being 204% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	603,406
Cost of Goods Sold	17,694
Intangible Assets	39,087
Liabilities, Current	276,760
Liabilities, Non-Current	20,815
Other Assets	35,142
Other Compr. Net Income	2,133
Other Expenses	10,227
Other Liabilities	721,589
Other Net Income	-113,000
Other Revenues	63,627
Property and Equipment	9,340
Research and Development	228,998
Selling, General and Administrative Expense	462,323

Output Variable	Value in 1000 USD
Assets	686,975
Liabilities	1,019,164
Expenses	719,242
Revenues	63,627
Stockholders Equity	-332,189
Net Income	-768,615
Comprehensive Net Income	-767,548
Economic Capital Ratio	-157%

